Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Sumitomo Pharma (4506 JP): Back in Black; Rebooting For Future With Focus On Regenerative Medicine

Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan

Sumitomo Pharma (4506 JP): Positive Momentum Persists, New Agreements Adds Steam

Sumitomo Pharma (4506 JP): Challenges Remain, But Slowly Getting There; North America Remains Key

Sumitomo Pharma (4506 JP): Robust 9MFY25 Revenues; Back in Black; Guidance Revised

Sumitomo Pharma (4506 JP): Q1FY25 Result Shows Early Sign of Performance Reversal

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sumitomo-pharma-co" target="_blank" data-smartkarma-citation="entities:1935:1" rel="noopener">Sumitomo Pharma (4506 JP)</a> revised revenue guidance for FY25 to ¥399B from previous ¥381B. New guidance represents 27% YoY growth.</li>
<li>This comes on the back of higher than expected sales in North American segment, which contributed 61% sales in 9MFY25.</li>
<li>Operating profit guidance have been revised to ¥43.2B from ¥30B on controlled cost and higher sales.</li>
</ul>



Sumitomo Pharma (4506 JP) revised revenue guidance for FY25 to ¥399B from previous ¥381B. New guidance represents 27% YoY growth.
This comes on the back of higher than expected sales in North American segment, which contributed 61% sales in 9MFY25.
Operating profit guidance have been revised to ¥43.2B from ¥30B on controlled cost and higher sales.


Sumitomo Pharma (4506 JP): Guidance Revised Upward for FY25 Driven by North America